Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.49 |
| ▸ | GRN | P28799 | 4/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.48 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535088 | 0.87 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL1535086 | 0.87 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL14436761 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL19083736 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL14530116 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL11740805 | 0.79 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Water SCHEMBL6544726 | 0.79 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL11740799 | 0.79 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL13485069 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL13484743 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G1B, PLA2G2E, PLA2G4A | ALDH1A1 2466/4885MEN1 1413/4885LMNA 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.